CJC-1295 vs Ipamorelin

They hit two different receptors. CJC-1295 acts on the GHRH receptor (the same pathway sermorelin and tesamorelin use), while ipamorelin hits the ghrelin receptor (the growth hormone secretagogue pathway). Stimulating both simultaneously produces a larger GH pulse than either alone - the effect is additive and partially synergistic. This is why clinical growth hormone peptide programs almost always use the combination instead of either compound as a monotherapy.

Clinically, no-DAC is preferred. The DAC (drug affinity complex) version extends CJC-1295's half-life from minutes to roughly a week, producing continuous GH elevation instead of the natural pulsatile pattern your body uses. That continuous bath of GH desensitizes receptors and disrupts IGF-1 feedback. The no-DAC version preserves pulsatility, which is how your endocrine system actually expects to work. Research-market raw peptide of both exists, but clinicians almost always use no-DAC.

At therapeutic doses, yes - this is the main reason ipamorelin replaced older GHRPs like GHRP-6 and hexarelin in clinical peptide programs. The older GHRPs caused significant hunger (via ghrelin activation spillover), cortisol elevation, and prolactin increases that made long-term use uncomfortable. Ipamorelin was specifically designed for receptor selectivity. At very high doses these effects can still appear, but within the normal 100-300mcg range, it is essentially clean on cortisol and prolactin.

Both peptides hit FDA Category 2 in September 2023, which made 503A compounding pharmacies unable to produce them for patients. The FDA specifically cited adverse events in early ipamorelin studies including a reported death during IV administration, along with insufficient safety data for CJC-1295. The February 2026 FDA announcement flagged both for reclassification review, but for now legitimate clinical programs have had to pivot to tesamorelin (FDA approved) or sermorelin (grandfathered).

CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. Ipamorelin works via Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH. They differ in FDA approval status, efficacy data, and cost.

CJC-1295 typically costs $35 - $70/mo, while Ipamorelin costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). Ipamorelin is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of Ipamorelin include Injection site reactions, Increased hunger, Headache. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.